XML 120 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Line Items]      
Capitalized research and development domestic expenses amortization period 5 years    
Capitalized research and development foreign expenses amortization period 15 years    
Change in valuation allowance $ 45,500,000 $ 2,000,000  
Percentage of corporations stock owned by stockholders to determine ownership change 5.00%    
Maximum threshold percentage increases over a three year period of corporations stock owned by stockholders for ownership change 50.00%    
Income tax penalties or interest $ 0 0  
Unrecognized tax benefits $ 9,578,000 $ 3,450,000 $ 0
Description of income tax examination The Company’s federal and State tax returns for all years, 2015 through 2023, remain subject to examination by taxing authorities due to the tax attribute carryforwards.    
Domestic Tax Authority      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards $ 51,200,000    
State and Local Jurisdiction      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards 74,800,000    
Federal Orphan Drug Credit      
Income Tax Disclosure [Line Items]      
Tax credit carryforward amount 24,800    
Research Tax Credit Carryforward | Domestic Tax Authority      
Income Tax Disclosure [Line Items]      
Tax credit carryforward amount 8,900,000    
Research Tax Credit Carryforward | State and Local Jurisdiction      
Income Tax Disclosure [Line Items]      
Tax credit carryforward amount $ 3,200,000    
Tax credit carryforward expiration year 2031    
Minimum      
Income Tax Disclosure [Line Items]      
Income tax examination year under examination 2015    
Maximum      
Income Tax Disclosure [Line Items]      
Income tax examination year under examination 2023